One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Personalising PARP inhibitor combinations for metastatic castration-resistant prostate cancer
Balancing quality and quantity of life in older patients with breast cancer
John Amuasi: calling for a socioecological approach to One Health
Recommitting to global solidarity: introducing the Kigali Call to Action
Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial
Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial
Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial – Authors' reply
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Feasibility of interrupting the transmission of soil-transmitted helminths: the DeWorm3 community cluster-randomised controlled trial in Benin, India, and Malawi
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
The Lancet One Health Commission: harnessing our interconnectedness for equitable, sustainable, and healthy socioecological systems
